drugset
drugset / Trial / NCT00052598

Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant

NCT00052598 ↗

Phase 1/2 Terminated 7 enrolled Fred Hutchinson Cancer Center National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase I/II trial is studies the side effects of giving therapeutic allogeneic lymphocytes together with aldesleukin and to see how well it works in treating patients with high-risk or recurrent myeloid leukemia after undergoing donor stem cell transplant. Biological therapies, such as therapeutic autologous lymphocytes, may stimulate the immune system in different ways and stop cancer cells from growing. Aldesleukin may stimulate the white blood cells to kill cancer cells. Giving therapeutic autologous lymphocytes together with aldesleukin may kill more cancer cells

Timeline

Start
2002-09
Primary completion
2009-11
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject aldesleukin Protein / enzyme biologic — Subcutaneous
Subject allogeneic CD8+ PR3-specific CTLs Cell therapy — Intravenous

Indications

acute myeloid leukemia with 11q23 abnormalities acute myeloid leukemia with multilineage dysplasia acute myeloid leukemia with t(8;21)(q22;q22) translocation acute myeloid leukemia, del(5q31-q32) acute myeloid leukemia, inv(16)(p13.1;q22) acute myeloid leukemia, t(16;16)(p13.1;q22) acute promyelocytic leukemia blast phase chronic myelogenous leukemia, BCR-ABL1 positive childhood acute myeloid leukemia childhood myelodysplastic syndrome leukemia, myeloid, accelerated-phase therapy related acute myeloid leukemia and myelodysplastic syndrome